Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo aims to free MDS patients from frequent blood transfusions

NCT ID NCT07096297

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 23 times

Summary

This study tests whether combining two drugs, luspatercept and darbepoetin alfa, can help people with a certain type of lower-risk myelodysplastic syndromes (MDS) need fewer blood transfusions. The trial enrolls 60 adults who currently rely on red blood cell transfusions. The goal is to see if the treatment allows them to go without transfusions for at least 12 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MDS (MYELODYSPLASTIC SYNDROME) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Harold C. Simmons Comprehensive Cancer Center of UT Southwestern

    NOT_YET_RECRUITING

    Dallas, Texas, 75235, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    NOT_YET_RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Yale University

    RECRUITING

    New Haven, Connecticut, 06510, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.